Rhythm Pharmaceuticals Inc (RYTM) posted $92.1 million in Q3 2026 net product sales, driven by a robust U.S. launch in acquired HO, expanding reimbursement, and a strategic LG Chem royalty buy-down.
This is the newest page. Registered accounts read further back.